Recommendations of CDC, the Infectious Disease Society of America, and the American Society of Blood and Marrow Transplantation

References

• Centers for Disease Control and Prevention. Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients: Recommendations of CDC, the Infectious Disease Society of America, and the American Society of Blood and Marrow Transplantation. Morbid Mortal Week Rep 2000;49:(No. RR-10):1–95.
   Google Scholar
• Centers for Disease Control and Prevention. 1999 USPHS/IDSA guideline for the prevention of opportunistic infections in persons infected with human immunodefi-ciency virus. Morbid Mortal Week Rep 1999;48:1–66.
   Google Scholar
• Institute of Medicine/Committee on Emerging Microbial Threats to Health. Emerging infections: micro-bial threats to health in the United States. Lederberg J, Shope RE, and Oaks SC Jr., editors Washington, DC: National Academy Press, 1992. Available at http:// books.nap.edu/books/0309047412/html/index.html>. Accessed June 28, 2000.
   Google Scholar
• CDC. Addressing emerging infectious disease threats: a prevention strategy for the United States. Atlanta, GA: US Department of Health and Human Services, Public Health Service, CDC, 1994. Available at http://www.cdc.gov/ncidod/publications/eid_plan>. Accessed May 17, 2000.
   Google Scholar
• CDC. USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus: a summary. Morbid Mortal Week Rep 1995;44(No. RR-8):1–34.
   Google Scholar
• CDC. 1997 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus. Morbid Mortal Week Rep 1997;46(No. RR-12):1–46.
   Google Scholar
• CDC. 1999 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus. Morbid Mortal Week Rep 1999;48(No. RR-10):1–66.
   Google Scholar
• Gross PA, Barrett TL, Dellinger EP et al. Purpose of qual-ity standards for infectious diseases. Glin Infect Dis 1994;18:421.
   PubMed Web of Science ®Google Scholar
• Appelbaum FR. Use of bone marrow and peripheral bloodstem cell transplantation in the treatment of cancer. CA Cancer y Clin 1996;46:142–64.
   PubMed Web of Science ®Google Scholar
• Kessinger A, Armitage JO. Use of peripheral stem cell sup-port of high-dose chemotherapy. In: DeVita VT Jr., Hellman S, Rosenberg SA, editors. Important advances in oncology 1993. Philadelphia, PA: J.B.Lippincott Co., 1993.
   Google Scholar
• Bortin MM, Horowitz MM, Gale RP et al. Changing trends in allogeneic bone marrow transplantation for leukemia in the 1980s. y Am Med Assoc 1992;268:607–12.
   Web of Science ®Google Scholar
• Sobocinski KA, Horowitz MM, Rowlings PA et al. Bone marrow transplantation - 1994: a report from the International Bone Marrow Transplant Registry and the North American Autologous Bone Marrow Transplant Registry. y Hematother 1994;3:95–102.
   Google Scholar
• Zittoun RA, Mandelli F, Willemze R et al. Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. N Engl .7 Med 1995;332:217–23.
   PubMed Web of Science ®Google Scholar
• Thomas ED, Clift RA, Fefer A et al. Marrow transplantation for the treatment of chronic myelogenous leukemia. Ann Intern Med 1986;104:155–63.
   PubMed Web of Science ®Google Scholar
• Storb R, Longton G, Anasetti C et al. Changing trends in marrow transplantation for aplastic anemia [Review]. Bone Marrow Transplant 1992;10\(suppl 1):45–52.
   Google Scholar
• Mackinnon S, Hows JM, Goldman JM et al. Bone marrow transplantation for chronic myeloid leukemia: the use of histocompatible unrelated volunteer donors. Exp Hematol 1990;18:421–5.
   Google Scholar
• Kernan NA, Bartsch G, Ash RC et al. Analysis of 462 trans-plantations from unrelated donors facilitated by the National Marrow Donor Program. N Engl y Med 1993;328:593–602.
   PubMed Web of Science ®Google Scholar
• Nademanee AP, Schmidt GM, Parker P et al. Outcome of matched unrelated donor bone marrow transplantation in patients with hematologic malignancies using molecular typing for donor selection and graft-versus-host disease prophylaxis regimen of cyclosporine, methotrexate, and prednisone. Blood 1995;86:1228–34.
   PubMed Web of Science ®Google Scholar
• Clift RA, Hansen JA, Thomas ED et al. Marrow transplant-ation from donors other than HLA-identical siblings. Transplant 1979;28:235–42.
   PubMed Web of Science ®Google Scholar
• Beatty PG, Clift RA, Mickelson EM et al. Marrow trans-plantation from related donors other than HLA-identical siblings. N Engl .7 Med 1985;313: 765–71.
   Google Scholar
• Ferrara JL, Deeg HJ. Graft-versus-host disease [Review]. N Engl .7 Med 1991;324: 667–74.
   Google Scholar
• Marmont AM, Horowitz MM, Gale RP et al. T-cell deple-tion of HLA-identical transplants in leukemia. Blood 1991;78:2120–30.
   PubMed Web of Science ®Google Scholar
• Rowlings PA. 1996 summary slides show current use and outcome of blood and marrow transplantation. Autologous Blood and Marrow Transplant Registry - North America: Autol Blood Marrow Transplant Reg Newsletter 1996;3: 6–12.
   Google Scholar
• Rubinstein P, Rosenfield RE, Adamson JW, Stevens CE. Stored placental blood for unrelated bone marrow reconsti-tution [Review]. Blood 1993;81:1679–90.
   PubMed Web of Science ®Google Scholar
• Kurtzberg J, Laughlin M, Graham ML et al. Placental blood as a source of hematopoietic stem cells for transplantation into unrelated recipients. N Engl y Med 1996;335:157–66.
   PubMed Web of Science ®Google Scholar
• Wagner JE, Rosenthal J, Sweetman R et al. Successful trans-plantation of HLA-matched and HLA-mismatched umbilical cord blood from unrelated donors: analysis of engraftment and acute graft-versus-host disease. Blood 1996;88:795–802.
   PubMed Web of Science ®Google Scholar
• Meropol NJ, Overmoyer BA, Stadtmauer EA. High-dose chemotherapy with autologous stem cell support for breast cancer. Oncology (Huntingt) 1992;6:53-60 and 63; discussion, 63–4,69; published erratum, Oncology (Huntingt) 1993;7: 105.
   Google Scholar
• Sullivan KM, Storek J, Kopecky KJ et al. Controlled trial of long-term administration of intravenous immunoglobulin to prevent late infection and chronic graft-vs-host disease after marrow transplantation: clinical outcome and effect on subsequent immune recovery. Biol Blood Marrow Transplant 1996;2:44–53.
   PubMedGoogle Scholar
• Lazarus HM, Vogelsang GB, Rowe JM. Prevention and treat-ment of acute graft-versus-host disease: the old and the new; a report from The Eastern Cooperative Oncology Group (ECOG) [Review]. Bone Marrow Transplant1997;19:577–600.
   Google Scholar
• Antman KH, Rowlings PA, Vaughn WP et al. High-dose chemotherapy with autologous hematopoietic stem cell support for breast cancer in North America. y Clin Oncol 1997;15:1870–9.
   PubMed Web of Science ®Google Scholar
• Nevill TJ, Shepherd JD, Nantel SH et al. Stem cell trans-plant-related mortality (TRM) 1985–1996: the Vancouver experience [Abstract 4426]. Blood 1997;90 [suppl 1 (part 2 of 2)]:373b.
   Google Scholar
• Duell T, van Lint MT, Ljungman P et al. Health and func-tional status of long-term survivors of bone marrow transplantation. Ann Intern Med 1997;126:189–92.
   Google Scholar
• Bush NE, Haberman M, Donaldson G, Sullivan KM. Quality of life of 125 adults surviving 6-18 years after bone marrow transplantation. Soc Sci Med 1995;40:479–90.
   PubMed Web of Science ®Google Scholar
• Ochs L, Shu X0, Miller J et al. Late infections after allo-geneic bone marrow transplantation: comparison of incidence in related and unrelated donor transplant recipi-ents. Blood 1995;86: 3979–86.
   Google Scholar
• Pearson ML. Guideline for prevention of intravascular device-related infections. Part I. Intravascular device-related infections: an overview. Am 7 Infra Control 1996;24: 262–93.
   Google Scholar
• Paulin T, Ringden 0, L8nnqvist B. Faster immunological recovery after bone marrow transplantation in patients withoutcytomegalovirusinfection.Transplant1985;3:377–84.
   Google Scholar
• Armitage JO. Bone marrow transplantation. N Engl 7 Med 1994;330:827–38.
   PubMed Web of Science ®Google Scholar
• Thomas ED, Storb R, Clift RA et al. Bone marrow trans-plantation (second of two parts) [Review]. N Engl 7 Med 1975;292:895–902.
   PubMed Web of Science ®Google Scholar
• Yeager AM, Vogelsang GB, Jones RJ et al. Induction of cuta-neous graft-versus-host disease by administration of cyclosporine to patients undergoing autologous bone mar-row transplantation for acute myeloid leukemia. Blood 1992;79:3031–5.
   PubMed Web of Science ®Google Scholar
• Rinehart JJ, Balcerzak SP, Sagone AL, LoBuglio AF. Effects of corticosteroids on human monocyte function. 7 Clin Invest 1974;54:1337–43.
   PubMed Web of Science ®Google Scholar
• Atkinson K, Horowitz MM, Gale RP et at Consensus among bone marrow transplanters for diagnosis, grading and treat-ment of chronic graft-versus-host disease. Bone Marrow Transplant 1989;4:247–54.
   PubMedGoogle Scholar
• Sullivan KM, Agura E, Anasetti C et al. Chronic graft-versus-host disease and other late complications of bone marrow transplantation. Semin Hematol 1991;28:250–9.
   PubMed Web of Science ®Google Scholar
• Witherspoon RP, Storb R, Ochs HD et al. Recovery of antibody production in human allogeneic marrow graft recipients: influence of time posttransplantation, the presence or absence of chronic graft-versus-host disease, and antithymocyte globulin treatment. Blood 1981;58: 360–8.
   PubMed Web of Science ®Google Scholar
• Lum LG, Munn NA, Schanfield MS, Storb R. Detection of specific antibody formation to recall antigens after human bone marrow transplantation. Blood 1986;67:582–7.
   Google Scholar
• Ambrosino DM, Molrine DC. Critical appraisal of immu-nization strategies for the prevention of infection in the compromised host. Hematol Oncol Clin North Am 1993;7:1027–50.
   PubMedGoogle Scholar
• Lum LG. Kinetics of immune reconstitution after human marrow transplantation. Blood 1987;69:369–80.
   PubMed Web of Science ®Google Scholar
• Shulman HM, Sullivan KM, Weiden PL et al. Chronic graft-versus-host syndrome in man: a long-term clinico-pathologic study of 20 Seattle patients. Am 7 Med 1980;69: 209–17.
   Google Scholar
• Izutsu KT, Sullivan KM, Schubert MM et al. Disordered salivary immunoglobulin secretion and sodium transport in human chronic graft-versus-host disease. Transplant 1983;35:441–6.
   PubMed Web of Science ®Google Scholar
• Aucouturier P, Barra A, Intrator L et al. Long lasting IgG subclass and antibacterial polysaccharide antibody defi-ciency after allogeneic bone marrow transplantation. Blood 1987;70:779–85.
   PubMed Web of Science ®Google Scholar
• Hughes WT, Armstrong D, Bodey GP et al. 1997 guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever [Review]. Clin Inject Dis 1997;25:551–73.
   Google Scholar
• Pizzo PA, Hathorn JW, Hiemenz J et al. Randomized trial comparing ceftazidime alone with combination antibiotic therapy in cancer patients with fever and neutropenia. N Engl .7 Med 1986;315:552–8.
   PubMed Web of Science ®Google Scholar
• Amgen, Inc. Filgrastim. In: Physician's desk reference. 54th edi-tion. Montvale, NJ: Medical Economics Company, Inc., 2000:528–33.
   Google Scholar
• Padley D, Koontz F, Trig ME et al. Bacterial contamination rates following processing of bone marrow and peripheral blood progenitor cell preparations. Transfusion 1996;36:53–6.
   PubMedGoogle Scholar
• National Marrow Donor Program. Standards: effective September 1, 1999. 17th edition. Minneapolis, MN: National Marrow Donor Program, 1999:1–35.
   Google Scholar
• Progenitor Cell Standards Task Force. Standards fir hematopoietic progenitor cells. Bethesda, MD: American Association of Blood Banks, 1996:1–36.
   Google Scholar
• Foundation for the Accreditation of Hematopoietic Cell Therapy. Standards for hematopoietic progenitor cell collection,pro-cessing and transplantation. 1st edition - North America. Omaha, NE: FAHCT Accreditation Office, 1996:1–58.
   Google Scholar
• Food and Drug Administration. Memorandum, Yune 8, 1995: recommendations for the deferral of current and recent inmates of correctional institutions as donors of whole blood, blood components, source leukogtes, and source plasma. Rockville, MD: US Department of Health and Human Services, Food and Drug Administration, 1995. Available at http://www.fda.gov/cber/bldmem/6_8_95.txt>. Accessed May 16,2000.
   Google Scholar
• American Association of Blood Banks. New uniform donor history questionnaire issued [Association bulletin 99-10]. Am Assoc Blood Banks News 1999;(Nov/Dec):13–21.
   Google Scholar
• CDC. Guidelines for preventing transmission of human immunodeficiency virus through transplantation of human tissue and organs. Morbid Mortal Week Repv 1994;43(No. RR-8):1–17.
   Google Scholar
• CDC. Public health service inter-agency guidelines for screening donors of blood, plasma, organs, tissues, and semen for evidence of hepatitis B and hepatitis C. Morbid Mortal Week Rep 1991;40(No. RR-4):1–17.
   Google Scholar
• Food and Drug Administration. Suitability determination for donors of human cellular and tissue-based products [Proposed rule]. Fed Reg 1999;64:52696-723. Available at http://www.fda.gov/cber/rules/suitdonor.pdf>. Accessed May 16,2000.
   Google Scholar
• Slavin MA, Meyers JD, Remington JS, Hackman RC. Toxoplasma gondii infection in marrow transplant recipients: a 20 year experience. Bone Marrow Transplant 1994;13: 549–57.
   PubMed Web of Science ®Google Scholar
• Wells GM, Woodward TE, Fiset P, Hornick RB. Rocky Mountain spotted fever caused by blood transfusion. 7 Am Med Assoc 1978;239:2763–65.
   PubMedGoogle Scholar
• Herwaldt BL, Kjemtrup AM, Conrad PA et al. Transfusion-transmitted babesiosis in Washington State: first reported case caused by a WA 1 -type parasite. y Infect Dis 1997;175:1259–62.
   PubMed Web of Science ®Google Scholar
• Dobroszycki J, Herwaldt BL, Boctor F et al. Cluster of trans-fusion-associated babesiosis cases traced to a single asymptomatic donor. y Am Med Assoc 1999;281:927–30.
   PubMedGoogle Scholar
• CDC. Q fever - California. Morbid Mortal Week Rep 1977;26:86–91.
   Google Scholar
• CDC. Transmission of Colorado tick fever virus by blood transfusion - Montana. Morbid Mortal Week Rep 1975;24:422–7.
   Google Scholar
• Klein MB, Miller JS, Nelson CM, Goodman JL. Primary bone marrow progenitors of both granulocytic and mono-cytic lineages are susceptible to infection with the agent of human granulocytic ehrlichiosis. y Infect Dis 1997;176:1405–9.
   Google Scholar
• American Association of Blood Banks. Standards for blood banks and transfusion services. 19th edition. Bethesda, MD: American Association of Blood Banks, 1999:1–98.
   Google Scholar
• Dharmasena F, Gordon-Smith EC. Transmission of malaria by bone marrow transplantation [Letter]. Transplant 1986;42:228.
   PubMed Web of Science ®Google Scholar
• Villeneuve L, Cassaing S, Magnaval JF et al. Plasmodium falciparum infection following allogeneic bone-marrow transplantation. Ann Trop Med Parasitol 1999;93:533–5.
   PubMed Web of Science ®Google Scholar
• Leiby DA, Fucci MH, Stumpf RJ. Trypanosoma cruzi in a low- to moderate-risk blood donor population: seropreva-lence and possible congenital transmission. Transfusion 1999;39:310–5.
   Google Scholar
• Moraes-Souza H, Bordin JO. Strategies for prevention of transfusion-associated Chagas' disease. Transfus Med Rev 1996;10:161–70.
   Google Scholar
• Altclas J, Jaimovich G, Milovic V et al. Chagas' disease after bone marrow transplantation. Bone Marrow Transplant 1996;18:947–8.
   Google Scholar
• Leiby DA, Lenes BA, Tibbals MA, Tames-Olmedo MT. Prospective evaluation of a patient with Tupanosoma cruzi infection transmitted by transfusion. New Engl y Med 1999;341:1237–9.
   Google Scholar
• Leiby DA, Read EJ, Lenes BA et al. Seroepidemiology of Trypanosoma cruzi, etiologic agent of Chagas' disease, in US blood donors. y Infect Dis 1997;176:1047–52.
   Google Scholar
• Dodd RY. Transmission of parasites by blood transfusion [Review]. Vox Sang 1998;74(su ppl 2):161–3.
   Google Scholar
• Dictar M, Sinagra A, Verón MT et al. Recipients and donors of bone marrow transplants suffering from Chagas' disease: management and preemptive therapy of parasitemia. Bone Marrow Transplant 1998;21:391–3.
   PubMedGoogle Scholar
• Food and Drug Administration. Guidance for industry: precautionary measures to reduce the possible risk of transmission of zoonoses by blood and blood products from xenotransplantation products recipients and their contacts - 12/23/99 [Draft guidance]. Rockville, MD: US Department of Health and Human Services, Food and Drug Administration, 1999:1–11. Available at http://wwwfda.gov/cber/guidelines.htm.AccessedMay 16,2000.
   Google Scholar
• CDC. Creutzfeldt-Jakob disease associated with cadaveric dura mater grafts -Japan, January 1979-May 1996. Morbid Mortal Week Rep 1997;46:1066–9.
   Google Scholar
• Food and Drug Administration. Guidance for industu: revisedprecautionary measures to reduce the possible risk of transmission of Creutzfildt-Yakob Disease (CYD) and new variant Creutzfildt-Yakob disease (nvCYD) by blood and blood products - 11123199. Rockville, MD: US Department of Health and Human Services, Food and Drug Administration, 1999:1–16. Available at http://www.fda.gov/cber/guide-lines.htm. Accessed May 16,2000.
   Google Scholar
• Will RG, Alpers MP, Dormont D et al. Infectious and spor-adic prion diseases. In: Prusiner SB, editor. Prion biology and diseases. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press, 1999:465–507.
   Google Scholar
• Food and Drug Administration. Memorandum, April 23, 1992: revised recommendations for the prevention of Human Immunodeficieng Virus (HIV) transmission by blood and blood products. Rockville, MD: US Department of Health and Human Services, Food and Drug Administration, 1992:1–24. Available at http://www.fda. gov/cber/memo.htm. Accessed May 16,2000.
   Google Scholar
• Pugatch D, Mileno M, Rich JD. Possible transmission of human immunodeficiency virus type 1 from body piercing. Clin Infect Dis 1998;26: 767–8.
   Google Scholar
• CDC. 1995 revised guidelines for prophylaxis against Pneumocystic carinii pneumonia for children infected with or perinatally exposed to human immunodeficiency virus. Morbid Mortal Week Rep 1995;44(No. RR-4):1–11.
   Google Scholar
• Attarian H, Bensinger WI, Buckner CD et al. Microbial con-tamination of peripheral blood stem cell collections. Bone Marrow Transplant 1996;17:699–702.
   PubMedGoogle Scholar
• Rowley SD, Davis J, Dick J et al. Bacterial contamination of bone marrow grafts intended for autologous and allogeneic bone marrow transplantation: incidence and clinical signif-icance. Transfusion 1988;28:109–12.
   Google Scholar
• Webb IJ, Coral FS, Andersen JW et al. Sources and sequelae of bacterial contamination of hematopoietic cell compon-ents: implications for the safety of hematotherapy and graft engineering. Transfusion 1996;36:782–8.
   PubMed Web of Science ®Google Scholar
• Meyers JD, Huff JC, Holmes KK et al. Parenterally trans-mitted hepatitis A associated with platelet transfusions: epidemiologic study of an outbreak in a marrow transplan-tation center. Ann Intern Med 1974;81:145–51.
   PubMed Web of Science ®Google Scholar
• Fountain D, Ralston M, Higgins N et al. Liquid nitrogen freezers: a potential source of microbial contamination of hematopoietic stem cell components. Transfusion 1997;37:585–91.
   PubMed Web of Science ®Google Scholar
• Nasser RM, Hajjar I, Sandhaus LM et al. Routine cultures of bone marrow and peripheral stem cell harvests: clinical impact, cost analysis, and review. Clin Infect Dis 1998;27: 886–8.
   Google Scholar
• FlakeAW,RoncaroloMG,PuckJMetal.Treatment of x-linked severe combined immunodeficiency by in utero transplantationof paternal bonemarrow.NEnglJ Med 1996;335:1806�10.
   Google Scholar
• Flake AW, Zanjani ED. In utero hematopoietic stem cell transplantation: a status report. J Am Med Assoc 1997;278:932�7.
   Google Scholar